SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
The Spectrum Pharmaceuticals class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum Pharmaceuticals had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, Spectrum Pharmaceuticals' public statements were materially false and misleading at all relevant times.SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period") have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit. The Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934. The Spectrum Pharmaceuticals class action lawsuit (Luo v. Spectrum Pharmaceuticals, Inc., No. 2:21-cv-01612) was commenced on August 31, 2021 and is pending in the District of Nevada.
圣迭戈，9月2021年7月/美通社/--Robbins Geller Rudman&Dowd LLP宣布，Spectrum PharmPharmticals，Inc.(纳斯达克市场代码：SPPI)证券的购买者和收购者在2018年12月27日至2021年8月5日，(“上课期间”)可在2021年11月1日之前寻求任命为SPECTRUM制药公司集体诉讼。这个SPECTRUM制药公司集体诉讼指控Spectrum制药公司及其某些高管违反了1934年的证券交易法。这个SPECTRUM制药公司集体诉讼(罗诉斯派勒姆制药公司(Lo v.Spectrum PharmPharmticals，Inc.)，编号2：21-cv-01612)于2021年8月31日目前正在内华达州地区待决。
If you wish to serve as lead plaintiff of the Spectrum Pharmaceuticals class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Spectrum Pharmaceutical class action lawsuit must be filed with the court no later than November 1, 2021.
如果你希望担任该案件的主要原告，SPECTRUM制药公司集体诉讼，请点击此处提供您的信息。你也可以通过拨打800/449-4900或通过电子邮件联系罗宾斯·盖勒律师J.C.桑切斯[受电子邮件保护]。首席原告动议SPECTRUM制药公司集体诉讼必须不迟于向法院提起2021年11月1日.
CASE ALLEGATIONS: Spectrum Pharmaceuticals is a biopharmaceutical company whose products under development include, among others, ROLONTIS (eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. In December 2018, Spectrum Pharmaceuticals submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for ROLONTIS as a treatment for chemotherapy-induced neutropenia (the "ROLONTIS BLA").
案件指控：SPECTRUM制药公司是一家生物制药公司，其正在开发的产品包括ROLONTIS(Eflapegrastim)，这是一种治疗化疗引起的中性粒细胞减少症的新型长效粒细胞集落刺激因子。2018年12月，Spectrum PharmPharmticals向美国食品和药物管理局(FDA)提交了一份生物制品许可证申请(BLA)，申请ROLONTIS作为治疗化疗引起的中性粒细胞减少症(ROLONTIS BLA)的药物。
The Spectrum Pharmaceuticals class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum Pharmaceuticals had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, Spectrum Pharmaceuticals' public statements were materially false and misleading at all relevant times.
这个SPECTRUM制药公司集体诉讼称，在整个集体期间，被告作出了虚假和误导性的陈述，并且没有披露：(I)ROLONTIS制造工厂维持着不完善的控制和/或程序；(Ii)上述缺陷降低了FDA批准目前形式的ROLONTIS BLA的可能性；(Iii)Spectrum PharmPharmticals因此严重夸大了ROLONTIS BLA的批准前景；(Iv)因此，Spectrum制药公司的公开声明是重大虚假的。
On August 6, 2021, Spectrum Pharmaceuticals announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of Spectrum Pharmaceuticals' manufacturing facility will be necessary. On this news, Spectrum Pharmaceuticals' stock price fell more than 21%, damaging investors.
2021年8月6日，Spectrum制药公司宣布收到FDA关于ROLONTIS BLA的完整回复信(“CRL”)。CRL列举了与制造有关的缺陷，并表示有必要对Spectrum制药公司的制造设施进行重新检查。这一消息传出后，Spectrum PharmPharmticals的股价下跌了21%以上，损害了投资者的利益。
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Spectrum Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Spectrum Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Spectrum Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery of the Spectrum Pharmaceuticals class action lawsuit is not dependent upon serving as lead plaintiff.
主要原告程序：1995年私人证券诉讼改革法案允许任何在课堂期间购买Spectrum PharmPharmticals证券的投资者寻求被任命为首席原告SPECTRUM制药公司集体诉讼。主要原告通常是在推定阶级所寻求的救济中具有最大经济利益的动因，该推定阶级也是推定阶级中的典型和适当的。主要原告代表所有其他班级成员指示SPECTRUM制药公司集体诉讼。主原告可以选择自己选择的律师事务所对SPECTRUM制药公司集体诉讼。投资者在未来任何潜在的经济复苏中分享的能力SPECTRUM制药公司集体诉讼不依赖于担任主要原告。
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions. Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors last year, more than double the amount recovered by any other securities plaintiffs' firm. Please visit http://www.rgrdlaw.com for more information.
关于罗宾斯·盖勒·鲁德曼律师事务所：Robbins Geller Rudman&Dowd LLP在全国9个办事处拥有200名律师，是美国最大的证券集体诉讼投资者代理律师事务所。罗宾斯·盖勒(Robbins Geller)的律师获得了历史上许多最大的股东追回，包括有史以来最大的证券集体诉讼追回-72亿美元在Re Enron Corp.SEC.立蒂格。在2020年ISS证券集体诉讼服务50强报告中，罗宾斯·盖勒在康复方面排名第一16亿美元对于去年的投资者来说，这是任何其他证券原告公司追回的金额的两倍多。如需更多信息，请访问http://www.rgrdlaw.com。
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
律师广告。过去的结果并不能保证未来的结果。我们任何一个办事处的律师都可以提供服务。
Contact:
联系方式：
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]
罗宾斯·盖勒·鲁德曼律师事务所百老汇西655号，圣地亚哥信箱：CA 92101J.C.桑切斯，800-449-4900[受电子邮件保护]
SOURCE Robbins Geller Rudman & Dowd LLP
来源：Robbins Geller Rudman&Dowd LLP
Related Links
相关链接
http://rgrdlaw.com
Http://rgrdlaw.com